Currently, only some AMPs with the ability to combat MDR bacteria have been approved by the FDA and already routinely used, such as Gramicidin (date of approval: 2005),104 Micafungin (2005),105 Anidulafungin (2006),106 Telavancin (2009),106 Ceftaroline (2010),5 Dalbavancin (2014),106 Oritavancin (2014),106 Caspofungin (2017),106 Ozenoxacin (2017),5 Tedizolid Phosphate (2015),5 and Omadacycline (2018).5 Most of them are against bacterial infection and administered either I.V. or topically.107,108 Some AMPs, not yet FDA approved, are being tested in clinical trials and listed in Table 4. Here, ADSL is linked to bacterial infectious disease.